HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol. METHODS: A post hoc analysis of the recently completed Treating to New Targets (TNT) study assessed the predictive value of HDL cholesterol levels in 9770 patients. The primary outcome measure was the time to a first major cardiovascular event, defined as death from coronary heart disease, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. The predictive relationship between HDL cholesterol levels at the third month of treatment with statins and the time to the first major cardiovascular event was assessed in univariate and multivariate analyses and was also assessed for specific LDL cholesterol strata, including subjects with LDL cholesterol levels below 70 mg per deciliter (1.8 mmol per liter). RESULTS: The HDL cholesterol level in patients receiving statins was predictive of major cardiovascular events across the TNT study cohort, both when HDL cholesterol was considered as a continuous variable and when subjects were stratified according to quintiles of HDL cholesterol level. When the analysis was stratified according to LDL cholesterol level in patients receiving statins, the relationship between HDL cholesterol level and major cardiovascular events was of borderline significance (P=0.05). Even among study subjects with LDL cholesterol levels below 70 mg per deciliter, those in the highest quintile of HDL cholesterol level were at less risk for major cardiovascular events than those in the lowest quintile (P=0.03). CONCLUSIONS: In this post hoc analysis, HDL cholesterol levels were predictive of major cardiovascular events in patients treated with statins. This relationship was also observed among patients with LDL cholesterol levels below 70 mg per deciliter. (ClinicalTrials.gov number, NCT00327691 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have shown that HDL cholesterol (HDL-C) levels under statin treatment remain an independent predictor of the risk of cardiovascular events in patients who have been treated with statins to lower LDL-C levels4”
From MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice (2012) · cites this paper as [4]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.151”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [151]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [292]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Self-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- 10.1001/jama.251.3.351 · DOI · Paper page
Cited by
Items 101–200 of 1,001
Ling, H., Waterworth, D. M., Stirnadel, H. A., Pollin, T. I., Barter, P. J., Kesäniemi, Y. A., Mahley, R. W., McPherson, R., Waeber, G., Bersot, T. P., et al. (2009) · Obesity · doi:10.1038/oby.2008.625 · Cited by 171
Self-citationPacifico, L., Bonci, E., Andreoli, G., Romaggioli, S., Di Miscio, R., Lombardo, C. V., & Chiesa, C. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.01.010 · Cited by 170
Update on strategies to increase HDL quantity and function
Duffy, D., & Rader, D. J. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.94 · Cited by 169
Ray, K. K., Nicholls, S. J., Buhr, K. A., Ginsberg, H. N., Johansson, J. O., Kalantar-Zadeh, K., Kulikowski, E., Toth, P. P., Wong, N., Sweeney, M., et al. (2020) · JAMA · doi:10.1001/jama.2020.3308 · Cited by 166
Dyslipidemia and Pediatric Obesity
Cook, S., & Kavey, R. E. W. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2011.09.003 · Cited by 165
“elevated total circulating LDL particles heighten the risk of entrapment in the subendothelial matrix, and decreased large HDL particles limit reverse cholesterol transport.(24,25) The atherogenicity of the combined dyslipidemia seen with childhood”
Jafri, H., Alsheikh-Ali, A. A., & Karas, R. H. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.069 · Cited by 162
2017 Taiwan lipid guidelines for high risk patients
Li, Y.-H., Ueng, K.-C., Jeng, J.-S., Charng, M.-J., Lin, T.-H., Chien, K.-L., Wang, C.-Y., Chao, T.-H., Liu, P.-Y., Su, C.-H., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.11.013 · Cited by 157
Matsuzaki, M., Yokoyama, M., Saito, Y., Origasa, H., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., Kita, T., et al. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1197 · Cited by 157
Dyslipidemia and cardiovascular risk: the importance of early prevention
Miller, M. J. (2009) · QJM · doi:10.1093/qjmed/hcp065 · Cited by 195
Advances in our understanding of the structure and functionality of edible fats and fat mimetics
Marangoni, A. G., van Duynhoven, J., Acevedo, N. C., Nicholson, R. A., & Patel, A. R. (2019) · Soft Matter · doi:10.1039/c9sm01704f · Cited by 171
Reiner, Ž. (2013) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.05.002 · Cited by 147
Paraoxonase and atherosclerosis-related cardiovascular diseases
Chistiakov, D. A., Melnichenko, A. А., Orekhov, A. N., & Bobryshev, Y. V. (2016) · Biochimie · doi:10.1016/j.biochi.2016.10.010 · Cited by 156
Soran, H., Hama, S., Yadav, R., & Durrington, P. N. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328355ca25 · Cited by 137
Carey, V. J., Bishop, L., Laranjo, N., Harshfield, B. J., Kwiat, C., & Sacks, F. M. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.05.002 · Cited by 149
Zhang, T., Chen, J., Tang, X., Luo, Q., Xu, D., & Yu, B. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1170-9 · Cited by 179
HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology
Rosenson, R. S., Brewer, H. B., Barter, P. J., Björkegren, J., Chapman, M. J., Gaudet, D., Kim, D. S., Niesor, E. J., Rye, K., Sacks, F. M., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.115 · Cited by 160
Self-citationCholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
Barter, P. J., & Rye, K.-A. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024075 · Cited by 146
“LDL cholesterol has been decreased to very low levels by treatment with statins (3).”
Self-citationSaeed, O., Otsuka, F., Polavarapu, R., Karmali, V., Weiss, D., Davis, T., Rostad, B., Pachura, K., Adams, L., Elliott, J., et al. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.240101 · Cited by 146
“Yet, even in this patient population, measures of cholesterol efflux potential such as HDL remain independent predictors of cardiovascular risk 22 .”
Mechanisms and Treatment of Dyslipidemia in Diabetes
Bahiru, E. M., Hsiao, R., Philipson, D. J., & Watson, K. E. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01455-w · Cited by 183
Clinical efficacy and safety of statins in managing cardiovascular risk
Kapur, N. K., & Musunuru, K. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1653 · Cited by 160
Ren, X., Chen, Z. A., Zheng, S., Tingting, H., Li, Y., Liu, W., & Hu, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154345 · Cited by 152
Khalesi, S., Sun, J., Buys, N., Jamshidi, A., Nikbakht-Nasrabadi, E., & Khosravi-Boroujeni, H. (2014) · European Journal of Nutrition · doi:10.1007/s00394-014-0720-1 · Cited by 138
Stein, E. A., Stroes, E. S. G., Steiner, G. A., Buckley, B. M., Capponi, A. M., Burgess, T., Niesor, E. J., Kallend, D. G., & Kastelein, J. J. P. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.02.061 · Cited by 136
Self-citationTriglycerides and HDL Cholesterol
Bitzur, R., Cohen, H., Kamari, Y., Shaish, A., & Harats, D. (2009) · Diabetes Care · doi:10.2337/dc09-s343 · Cited by 132
Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting
Cziraky, M. J., Watson, K. E., & Talbert, R. L. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s8-a.1 · Cited by 131
Heresi, G. A., Aytekin, M., Newman, J. E., DiDonato, J. A., & Dweik, R. A. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0007oc · Cited by 136
“However, the Framingham Study (4) and more recent studies (5, 42) have also shown that HDL-C is a protective factor for cardiovascular events, independent of the levels of LDL-C.”
Davidson, M., Meyer, P. M., Haffner, S., Feinstein, S., D’Agostino, R., Kondos, G. T., Perez, A., Chen, Z., & Mazzone, T. (2008) · Circulation · doi:10.1161/circulationaha.107.746610 · Cited by 128
deGoma, E. M., Leeper, N. J., & Heidenreich, P. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.086 · Cited by 133
High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality
Silbernagel, G., Schottker, B., Appelbaum, S., Scharnagl, H., Kleber, M. E., Grammer, T. B., Ritsch, A., Mons, U., Holleczek, B., Goliasch, G., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht343 · Cited by 123
Nash, M. S., Groah, S. L., Gater, D. R., Dyson-Hudson, T. A., Lieberman, J. A., Myers, J., Sabharwal, S., Taylor, A. J., & Consortium for Spinal Cord Medicine (2018) · Topics in Spinal Cord Injury Rehabilitation · doi:10.1310/sci2404-379 · Cited by 126
Olatona, F. A., Onabanjo, O. O., Ugbaja, R. N., Nnoaham, K. E., & Adelekan, D. A. (2018) · Journal of Health Population and Nutrition · doi:10.1186/s41043-018-0152-2 · Cited by 157
Bardini, G., Rotella, C. M., & Giannini, S. (2012) · The Review of Diabetic Studies · doi:10.1900/rds.2012.9.82 · Cited by 138
How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators
Cooney, M. T., Dudina, A., De Bacquer, D., Fitzgerald, A., Conroy, R., Sans, S., Menotti, A., De Backer, G., Jousilahti, P., Keil, U., et al. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283213140 · Cited by 121
Mouse Models of Experimental Autoimmune Uveitis
Caspi, R. R., Silver, P. B., Luger, D., Tang, J., Cortes, L. M., Pennesi, G., Mattapallil, M. J., & Chan, C.-C. (2008) · Ophthalmic Research · doi:10.1159/000119871 · Cited by 118
Fuller, N. R., Caterson, I. D., Sainsbury, A., Denyer, G., Fong, M., Gerofi, J., Baqleh, K., Williams, K. H., Lau, N. S., & Markovic, T. P. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.096925 · Cited by 115
Nicholls, S. J., Ruotolo, G., Brewer, H. B., Kane, J. P., Wang, M.-D., Krueger, K. A., Adelman, S. J., Nissen, S. E., & Rader, D. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.013 · Cited by 114
Distinctive Biological Correlates of Positive Psychological Well-Being in Older Men and Women
Steptoe, A., Demakakos, P., de Oliveira, C., & Wardle, J. (2012) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31824f82c8 · Cited by 112
High-Density Lipoprotein and Atherosclerosis: The Role of Antioxidant Activity
Bandeali, S. J., & Farmer, J. A. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0235-2 · Cited by 120
Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease
Zewinger, S., Kleber, M. E., Rohrer, L., Lehmann, M., Triem, S., Jennings, R. T., Petrakis, I., Dressel, A., Lepper, P. M., Scharnagl, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx118 · Cited by 120
Robert, J., Button, E. B., Yuen, B., Gilmour, M., Kang, K., Bahrabadi, A., Stukas, S., Zhao, W., Kulic, I., & Wellington, C. L. (2017) · eLife · doi:10.7554/elife.29595 · Cited by 111
“By contrast, the major circulating lipoprotein in humans is LDL, which is mechanistically linked to vascular dysfunction and cardiovascular disease (Barter et al., 2007).”
Chen, L., Ma, M.-Y., Sun, M., Jiang, L.-Y., Zhao, X.-T., Fang, X.-X., Man Lam, S., Shui, G.-H., Luo, J., Shi, X.-J., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.ra119000201 · Cited by 109
HDL-C: Role as a risk modifier
Barter, P. J. (2011) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(11)70885-6 · Cited by 135
Self-citationMoradi, H., Streja, E., Kashyap, M. L., Vaziri, N. D., Fonarow, G. C., & Kalantar‐Zadeh, K. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu022 · Cited by 117
The Changing Face of HDL and the Best Way to Measure It
Karathanasis, S. K., Freeman, L. A., Gordon, S. M., & Remaley, A. T. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.257725 · Cited by 109
Armstrong, N. M., An, Y., Beason-Held, L., Doshi, J., Erus, G., Ferrucci, L., Davatzikos, C., & Resnick, S. M. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.05.020 · Cited by 108
Sasaki, J. D., Ikeda, Y., Kuribayashi, T., Kajiwara, K., Biro, S., Yamamoto, K., Ageta, M., Kobori, S., Saikawa, T., Otonari, T., et al. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.017 · Cited by 114
Kratzer, A., Giral, H., & Landmesser, U. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu139 · Cited by 109
Monocyte adhesion to the endothelium is an initial stage of atherosclerosis development
Čejková, S., Lesná, I. K., & Poledne, R. (2015) · Cor et Vasa · doi:10.1016/j.crvasa.2015.08.002 · Cited by 115
Daily Apple versus Dried Plum: Impact on Cardiovascular Disease Risk Factors in Postmenopausal Women
Chai, S. C., Hooshmand, S., Saadat, R. L., Payton, M. E., Brummel‐Smith, K. V., & Arjmandi, B. H. (2012) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2012.05.005 · Cited by 110
Three-dimensional models of HDL apoA-I: implications for its assembly and function
Thomas, M. J., Bhat, S., & Sorci-Thomas, M. G. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800010-jlr200 · Cited by 107
Jafri, H., Alsheikh-Ali, A. A., & Karas, R. H. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-12-201012210-00006 · Cited by 106
High-density lipoprotein, beta cells, and diabetes
von Eckardstein, A., & Widmann, C. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu143 · Cited by 105
HDL Cholesterol Is Not Associated with Lower Mortality in Patients with Kidney Dysfunction
Zewinger, S., Speer, T., Kleber, M. E., Scharnagl, H., Woitas, R., Lepper, P. M., Pfahler, K., Seiler, S., Heine, G. H., März, W., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013050482 · Cited by 103
Molecular Mechanisms of HDL-Cholesterol Elevation by Statins and Its Effects on HDL Functions
Yamashita, S., Tsubakio‐Yamamoto, K., Ohama, T., Nakagawa-Toyama, Y., & Nishida, M. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.5405 · Cited by 114
microRNAs in the onset and development of cardiovascular disease
Vickers, K. C., Rye, K., & Tabet, F. (2013) · Clinical Science · doi:10.1042/cs20130203 · Cited by 107
Barter, P. J. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.014 · Cited by 103
Self-citationCombined therapy in the treatment of dyslipidemia
Reiner, Ž. (2010) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00764.x · Cited by 100
HDL endocytosis and resecretion
Röhrl, C., & Stangl, H. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.07.014 · Cited by 101
Orozco-Beltran, D., Gil-Guillen, V. F., Redon, J., Martin-Moreno, J. M., Pallares-Carratala, V., Navarro-Perez, J., Valls-Roca, F., Sanchis-Domenech, C., Fernandez-Gimenez, A., Perez-Navarro, A., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0186196 · Cited by 99
Acharjee, S., Boden, W. E., Hartigan, P. M., Teo, K. K., Maron, D. J., Sedlis, S. P., Kostuk, W. J., Spertus, J. A., Dada, M. R., CHAITMAN, B. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.051 · Cited by 112
Zhang, L., Jin, H., Guo, X., Yang, Z., Zhao, L., Tang, S., Ping, M., Wu, K., Nie, Y., Pan, Y., et al. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.05.012 · Cited by 105
HDL and cardiovascular disease
Nicholls, S. J., & Nelson, A. J. (2019) · Pathology · doi:10.1016/j.pathol.2018.10.017 · Cited by 118
Enomoto, M., Adachi, H., Hirai, Y., Fukami, A., Satoh, A., Otsuka, M., Kumagae, S., Nanjo, Y., Yoshikawa, K., Esaki, E., et al. (2011) · Journal of Lipids · doi:10.1155/2011/549137 · Cited by 112
Ancelin, M., Carrière, I., Boulenger, J., Malafosse, A., Stewart, R. J., Cristol, J., Ritchie, K. A., Chaudieu, I., & Dupuy, A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.011 · Cited by 107
Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo
Sacks, F. M., Rudel, L. L., Conner, A., Akeefe, H., Kostner, G., Baki, T., Rothblat, G., de la Llera-Moya, M., Asztalos, B., Perlman, T., et al. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800622-jlr200 · Cited by 97
The Evolving Role of HDL in the Treatment of High-Risk Patients with Cardiovascular Disease
Brewer, H. B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0163 · Cited by 102
Beginning to Understand High-Density Lipoproteins
Santos‐Gallego, C. G., Badimon, J. J., & Rosenson, R. S. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.001 · Cited by 102
Role of Niacin in Current Clinical Practice: A Systematic Review
Garg, A., Sharma, A., Krishnamoorthy, P. M., Garg, J., Virmani, D., Sharma, T., Stefanini, G. G., Kostis, J. B., Mukherjee, D., & Sikorskaya, E. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.07.038 · Cited by 104
Lehto, S. M., Hintikka, J. J., NISKANEN, L. K., Tolmunen, T., Koivumaa-Honkanen, H. T., Honkalampi, K. M., & Viinamäki, H. T. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.05.021 · Cited by 106
Comparison of Serum Lipid Values in Subjects With and Without the Metabolic Syndrome
Cordero, A., Laclaustra, M., León, M., Casasnovas, J. A., Grima, A., Luengo, E., Ordoñez, B., Martínez, C. B., Bes, M., Pascual, I., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.03.079 · Cited by 100
de Haan, W., de Vries-van der Weij, J., van der Hoorn, J. W. A., Gautier, T., van der Hoogt, C. C., Westerterp, M., Romijn, J. A., Jukema, J. W., Havekes, L. M., Princen, H. M. G., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.761965 · Cited by 95
Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
Kim, N. H., & Kim, S. G. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0001 · Cited by 104
Nicholls, S. J., Gordon, A., Johannson, J., Ballantyne, C. M., Barter, P. J., Brewer, H. B., Kastelein, J. J. P., Wong, N. C. W., Borgman, M., & Nissen, S. E. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6373-5 · Cited by 97
Self-citationThe Human Paraoxonase Gene Cluster As a Target in the Treatment of Atherosclerosis
She, Z., Chen, H., Yan, Y., Li, H., & Liu, D. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3774 · Cited by 101
Prevalence of dyslipidemia in iran: a systematic review and meta-analysis study.
Tabatabaei‐Malazy, O., Qorbani, M., Samavat, T., Sharifi, F., Larijani, B. A., & Fakhrzadeh, H. (2014) · PubMed Central · Cited by 96
Piltonen, T., Puurunen, J., Hedberg, P., Ruokonen, A., Mutt, S. J., Herzig, K. H., Nissinen, A., Morin-Papunen, L., & Tapanainen, J. S. (2012) · Human Reproduction · doi:10.1093/humrep/des225 · Cited by 94
Evidence-based goals in LDL-C reduction
Soran, H., Dent, R., & Durrington, P. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1069-7 · Cited by 92
Wan, K., Zhao, J., Huang, H., Zhang, Q., Chen, X., Zeng, Z., Zhang, L., & Chen, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123521 · Cited by 90
High-density lipoprotein and the acute phase response
Jahangiri, A. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328337278b · Cited by 92
Jenkins, D. J. A., Chiavaroli, L., Wong, J. M. W., Kendall, C., Lewis, G. F., Vidgen, E., Connelly, P. W., Leiter, L. A., Josse, R. G., & Lamarche, B. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.092128 · Cited by 92
Regulation of signal transduction by HDL
Mineo, C., & Shaul, P. W. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r039479 · Cited by 105
Regulation of ABCA1 functions by signaling pathways
Liu, Y., & Tang, C. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.08.015 · Cited by 90
Cordero, A., Andres, E. M., Ordoñez, B., León, M., Laclaustra, M., Grima, A., Luengo, E., Moreno, J., Bes, M., Pascual, I., et al. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.07.008 · Cited by 99
Keating, G. M. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11207690-000000000-00000 · Cited by 102
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 105
The role of the lymphatic system in cholesterol transport
Huang, L., Elvington, A., & Randolph, G. J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00182 · Cited by 106
Oxidized lipoprotein lipids and atherosclerosis
Ahotupa, M. O. (2017) · Free Radical Research · doi:10.1080/10715762.2017.1319944 · Cited by 90
Perveen, S., Shahbaz, M., Keshavjee, K., & Guergachi, A. (2019) · IEEE Access · doi:10.1109/access.2018.2884249 · Cited by 87
Roh, E., Ko, S.-H., Kwon, H.-S., Kim, N. H., Kim, J. H., Kim, C. S., Song, K.-H., Won, J. C., Kim, D. J., Choi, S. H., et al. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.6.433 · Cited by 87
Gotto, A. M., Cannon, C. P., Li, X. S., Vaidya, S., Kher, U., Brinton, E. A., Davidson, M., Moon, J. E., Shah, S., Dansky, H. M., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.041 · Cited by 86
“In patients with existing disease, low levels of high-density lipoprotein (HDL) cholesterol is associated with increased risk even when LDL cholesterol is reduced to low levels with statin therapy.(3) Inhibition of cholesteryl”
BackgroundSelf-citationHigh-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity
Rohatgi, A. K. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.05.004 · Cited by 95
Joo, H. J., Cho, S.-A., Hong, S. J., Hur, S., Bae, J., Choi, D., Ahn, Y., Park, J., Choi, R. K., Choi, D., et al. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0374-5 · Cited by 85
Gimelli, A., Rossi, G., Landi, P., Marzullo, P., Iervasi, G., L’Abbate, A., & Rovai, D. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.055954 · Cited by 89
Aguíar, C., Alegría, E., Bonadonna, R. C., Catapano, A. L., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hâncu, N., et al. (2015) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(15)30001-5 · Cited by 90
“8 mmol/L) [35].”
Effect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression
Kaur, N., Pandey, A. K., Negi, H., Shafiq, N., Reddy, S., Kaur, H., Chadha, N., & Malhotra, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094585 · Cited by 91
Sex Differences in the Associations Between Lipid Levels and Incident Dementia
Ancelin, M.-L., Ripoche, E., Dupuy, A.-M., Barberger-Gateau, P., Auriacombe, S., Rouaud, O., Berr, C., Carrière, I., & Ritchie, K. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-121228 · Cited by 82
Ramprasath, T., Murugan, P. S., Prabakaran, A. D., Gomathi, P., Rathinavel, A., & Selvam, G. S. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.02.097 · Cited by 92
Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence
Preiss, D., & Sattar, N. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03490.x · Cited by 82
Haraguchi, Y., Toh, R., Hasokawa, M., Nakajima, H., Honjo, T., Otsui, K., Mori, K., Miyamoto–Sasaki, M., Shinohara, M., Nishimura, K., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.03.009 · Cited by 82
Huang, C.-Y., Lin, F.-Y., Shih, C.-M., Au, H.-K., Chang, Y.-J., Nakagami, H., Morishita, R., Chang, N.-C., Shyu, K.-G., & Chen, J.-W. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.248617 · Cited by 80
Metadata
- Authors
- Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C.
- Affiliations
- The Heart Research Institute (AU)
- Cornell University (US)
- SUNY Downstate Health Sciences University (US)
- Pfizer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Alabama (US)
- Institut Pasteur de Lille (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-27
- Volume
- 357
- Issue
- 13
- Pages
- 1301-1310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158057499
- Cited by
- 1,610
- References
- 24
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 34 · 2023: 48 · 2022: 36 · 2021: 51 · 2020: 79 · 2019: 72 · 2018: 59 · 2017: 75 · 2016: 90 · 2015: 106 · 2014: 128 · 2013: 126 · 2012: 130
- FWCI
- 113.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HDL cholesterol, LDL cholesterol, very low LDL cholesterol, major cardiovascular events, statin therapy, cardiovascular risk prediction, coronary artery disease, myocardial infarction, stroke, low HDL cholesterol
- MeSH terms
- Atorvastatin, Adult, Aged, Anticholesteremic Agents, Apolipoproteins, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Risk, Multivariate Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.